iBio Q1 FY2027 earnings: net loss widens to $7.55M

iBio plans first-in-human studies of IBIO-610 in the first half of 2027, after advancing toward an IND-equivalent filing by year-end 2026.

Available on EDGAR 11/10/2026 - 04:36 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:36 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

iBio, Inc. reported revenue of $1.075 million for the first quarter of fiscal 2027, compared with $100,000 in the year-earlier quarter. Net loss was $7.551 million, compared with $5.720 million. Research and development expense was $6.650 million, compared with $3.550 million. Cash and cash equivalents were $45.435 million as of September 30, 2026, compared with $56.395 million as of June 30, 2026.

iBio said it presented additional preclinical data concerning IBIO-610’s potential for fat-selective weight loss with GLP-1 therapy, and completed dosing in the single ascending dose portion of IBIO-600’s Phase 1 trial.

1 point · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

How the balance works

Positive

• Moderate pointRevenue was $1.075 million, versus $100,000 in the year-earlier quarter.

Negative

• Moderate pointNet loss was $7.551 million, versus $5.720 million in the year-earlier quarter.

Filing Explained

iBio reported 64,307,256 common shares issued and outstanding at September 30, 2026, versus 55,698,561 at June 30, 2026; for holders whose share counts did not change, the larger total means each holds a smaller percentage of the company.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Revenue: $1.075 million Net loss: $7.551 million Research and development expense: $6.650 million +2 more

5 metrics

Revenue $1.075 million Three months ended September 30, 2026; $100,000 for the three months ended September 30, 2025

Net loss $7.551 million Three months ended September 30, 2026; $5.720 million for the three months ended September 30, 2025

Research and development expense $6.650 million Three months ended September 30, 2026; $3.550 million for the three months ended September 30, 2025

Loss per common share, basic and diluted ($0.05) Three months ended September 30, 2026; ($0.11) for the three months ended September 30, 2025

Cash and cash equivalents $45.435 million As of September 30, 2026; $56.395 million as of June 30, 2026

Key Terms

GLP-1 therapy, single ascending dose, multiple ascending dose, IND-equivalent filing

4 terms

GLP-1 therapy medical

"in combination with GLP-1 therapy"

GLP-1 therapy uses drugs that mimic the gut hormone glucagon-like peptide-1 to help control blood sugar and often reduce appetite and body weight; think of it as a thermostat for appetite and insulin that helps the body respond more appropriately after eating. It matters to investors because these treatments can address large markets for diabetes and obesity, drive drug sales, affect company valuations, and influence healthcare costs and prescribing patterns.

single ascending dose medical

"single ascending dose portion of the Phase 1 clinical trial"

A single ascending dose is a method used in testing new medicines where small amounts are given to participants, gradually increasing each time to find the safest and most effective dose. For investors, it provides important information about a drug’s safety and potential, helping gauge the progress and prospects of a pharmaceutical development.

multiple ascending dose medical

"multiple ascending dose portion of the Phase 1 clinical trial"

A multiple ascending dose is a method used in testing new medicines where small groups of people receive gradually larger amounts of the drug over time. This approach helps researchers find the safest and most effective dose without causing too many side effects. For investors, it signals ongoing steps in drug development that can impact a company's potential success or approval prospects.

IND-equivalent filing regulatory

"advancing toward an IND-equivalent filing"

Earnings Snapshot

Revenue: $1.075 million

First quarter of fiscal year 2027; three months ended September 30, 2026

Revenue $1.075 million Compared with $100,000 for the three months ended September 30, 2025.

Net loss $7.551 million Compared with $5.720 million for the three months ended September 30, 2025.

Research and development expense $6.650 million Compared with $3.550 million for the three months ended September 30, 2025.

Loss per common share, basic and diluted ($0.05) Compared with ($0.11) for the three months ended September 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What revenue did IBIO report for the first quarter of fiscal 2027?

IBIO reported $1.075 million in revenue for the three months ended September 30, 2026, compared with $100,000 for the three months ended September 30, 2025.

What was IBIO's net loss in the first quarter of fiscal 2027?

IBIO reported a $7.551 million net loss for the three months ended September 30, 2026, compared with a $5.720 million net loss for the three months ended September 30, 2025.

When does IBIO plan to begin human studies of IBIO-610?

iBio plans to initiate first-in-human studies in the first half of 2027, while advancing toward an IND-equivalent filing by the end of 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001420720false00014207202026-11-102026-11-10

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 10, 2026

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

​	​
001-35023	26-2797813
(Commission File Number)	(IRS Employer Identification No.)

​

11750 Sorrento Valley Road Suite 200

San Diego, California 92121

(Address of principal executive offices and zip code)

(979) 446-0027

(Registrant’s telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​	​	​
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	IBIO	The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

​

​

​

​

Item 2.02. Results of Operations and Financial Condition.

On November 10, 2026, iBio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

​

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

​

Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits

​	​	​
Exhibit No.	​ ​ ​	Description
99.1	​	Press Release, issued by iBio, Inc. dated November 10, 2026
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​	​
Date: November 10, 2026	IBIO, INC.
​	By:	/s/ Marc A. Banjak
		Name:	Marc A. Banjak
​	​	Title:	Chief Legal Officer

​

Exhibit 99.1

iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update

Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy

Completed dosing in the single ascending dose portion of the Phase 1 clinical trial of IBIO-600

Plans to participate in upcoming scientific and investor conferences

SAN DIEGO, November 10, 2026 -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the first quarter of fiscal year 2027, ended September 30, 2026, and provided a corporate update on its progress.

“This was a quarter of focus and execution as we advanced our portfolio of long-acting antibody therapeutics designed to address important challenges in obesity care,” said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. “The data presented at EASD strengthen our conviction in IBIO-610’s potential to deliver high-quality weight loss and provide important preclinical validation as we advance toward an IND-equivalent filing by the end of 2026, with plans to initiate first-in-human studies in the first half of 2027. We also anticipate advancing IBIO-600 in the multiple ascending dose portion of the Phase 1 trial in the first quarter of 2027 and progressing our preclinical programs that aim to address the entire spectrum of cardiometabolic disease care. Together, this progress brings us closer to our broader goal of helping people living with obesity achieve high-quality weight loss and better long-term health.”

First Fiscal Quarter 2027 & Recent Corporate Updates

· Presented additional preclinical body composition data from a study of IBIO-610, iBio’s long-acting Activin E antibody, in obese non-human primates (NHPs) at the European Association for the Study of Diabetes (EASD) Annual Meeting on October 1st.

o At week eight, fat accounted for 93% of the weight lost by NHPs receiving IBIO-610 in combination with semaglutide, compared with 77% for NHPs receiving semaglutide alone. Lean mass accounted for 6% and 22% of weight lost, respectively.

o These preclinical findings further support the potential of IBIO-610 to improve body composition, both as a standalone therapy and in combination with GLP-1 receptor agonists.

o iBio expects to initiate first-in-human trials of IBIO-610 in the first half of 2027.

· Completed dosing in the single ascending dose (SAD) portion of the first-in-human Phase 1 clinical trial of IBIO-600, iBio’s long-acting anti-myostatin antibody being developed to preserve muscle and improve body composition.

o iBio anticipates interim Phase 1 data of the SAD study in the first quarter of 2027.

o The multiple ascending dose portion of the Phase 1 clinical trial is anticipated to start in the first quarter of 2027.

· Plans to participate in upcoming scientific and investor conferences, including:

o Guggenheim Healthcare Innovation Conference: November 9-11, 2026

o ObesityWeek 2026: November 14-17, 2026

o Protein & Antibody Engineering (PEGS) Europe 2026: November 16-19, 2026

o Jefferies Global Healthcare Conference: November 16-19, 2026

o Piper Sandler 38th Annual Healthcare Conference: December 1-3, 2026

o Amylin-Based Therapeutics Summit: December 1-3, 2026

Financial Results

· Revenues for the three months ended September 30, 2026 were approximately $1.1 million, an increase of $1.0 over the $0.1 million in revenue for the three months ended September 30, 2025.

· Research and Development (“R&D”) expenses for the three months ended September 30, 2026 and 2025 were approximately $6.7 million and $3.6 million, respectively, an increase of approximately $3.1 million or approximately 87%. The increase in R&D expenses is primarily due to increased spending of approximately $2.6 million for consultants and outside services supporting our R&D efforts, including the IBIO-600 Phase 1 human clinical trial, NHP studies and CMC activities, and an increase of approximately $0.3 million in personnel costs as a result of advancing research activities for our IBIO-600, IBIO-610, and IBIO-800 programs and other preclinical pipeline assets.

· General and Administrative expenses for the three months ended September 30, 2026 and September 30, 2025, were approximately $2.8 million and $2.5 million, respectively, an increase of approximately $0.3 million or approximately 10%. The increase is primarily attributable to an increase in personnel costs and legal fees.

· iBio held cash and cash equivalents and investments in debt securities of approximately $76.7 million as of September 30, 2026.

About iBio, Inc.

iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

For more information, visit www.ibioinc.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements include, among others, statements regarding IBIO-610’s potential to deliver high-quality weight loss and provide important preclinical validation; iBio advancing toward an IND-equivalent filing for IBIO-610 by the end of 2026, with plans to initiate first-in-human studies in the first half of 2027; advancing IBIO-600 in the multiple ascending dose portion of the Phase 1 trial in the first quarter of 2027 and progressing iBio’s preclinical programs that aim to address the entire spectrum of cardiometabolic disease care; iBio helping people living with obesity achieve high-quality weight loss and better long-term health; the potential that adding IBIO-610 to GLP-1 therapy may improve the quality of weight loss by increasing the proportion of weight lost from fat while preserving muscle; initiating first-in-human trials of IBIO-610 in the first half of 2027; anticipated interim Phase 1 data of the SAD study in the first quarter of 2027; the multiple ascending dose portion of the Phase 1 clinical trial for IBIO-600 anticipated to start in the first quarter of 2027; and iBio’s planned participation in upcoming conferences. These statements reflect iBio’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks associated with meeting anticipated timelines, including an IND-equivalent filing for IBIO-610 by the end of 2026, initiating first-in-human studies in the first half of 2027, advancing IBIO-600 in the multiple ascending dose portion of the Phase 1 trial in the first quarter of 2027, initiating first-in-human trials of IBIO-610 in the first half of 2027 and the multiple ascending dose portion of the Phase 1 clinical trial for IBIO-600 starting in the first quarter of 2027 clinical trial enrollment and execution, the possibility that preclinical findings will not be

​

replicated in humans, product development and regulatory approval, and the other risks described in iBio’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended June 30, 2026, and subsequent filings.

Forward-looking statements speak only as of the date of this release. iBio undertakes no obligation to update them except as required by law.

Investor Contact

Matt Beck
astr partners
matthew.beck@astrpartners.com
(917) 415-1750

Media Contact

Jason Braco, Ph.D.
Valence Communications
jason@valencecomms.com

​

iBio, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited; in thousands, except per share amounts)

​

​	​	​	​	​	​	​
​	​	Three Months Ended
​	​	September 30,
​	​ ​ ​	2026		​ ​ ​	2025
​	​	​	​	​	​	​
Revenue	​	$	1,075	​	$	100
​	​	​	​	​	​	​
Operating expenses:	​	​	​	​	​	​
Research and development	​	​	6,650	​	​	3,550
General and administrative	​	​	2,763	​	​	2,501
Total operating expenses	​	​	9,413	​	​	6,051
​	​	​	​	​	​	​
Operating loss	​	​	(8,338)	​	​	(5,951)
​	​	​	​	​	​	​
Other income (expense):	​	​	​	​	​	​
Interest income	​	​	787	​	​	265
Interest expense	​	​	—	​	​	(34)
Total other income	​	​	787	​	​	231
​	​	​	​	​	​	​
Net loss before income taxes	​	​	(7,551)	​	​	(5,720)
​	​	​	​	​	​	​
Income tax expense	​	​	—	​	​	—
​	​	​	​	​	​	​
Net loss	​	$	(7,551)	​	$	(5,720)
​	​	​	​	​	​	​
Comprehensive loss:	​	​	​	​	​	​
Net loss	​	$	(7,551)	​	$	(5,720)
Other comprehensive loss - unrealized loss on debt securities	​	​	(78)	​	​	(15)
​	​	​	​	​	​	​
Comprehensive loss	​	$	(7,629)	​	$	(5,735)
​	​	​	​	​	​	​
Loss per common share - basic and diluted	​	$	(0.05)	​	$	(0.11)
​	​	​	​	​	​	​
Weighted-average common shares outstanding - basic and diluted - see Note 16	​	​	151,574	​	​	52,981

​

​

iBio, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

​

​	​	September 30,		​	June 30,		​
​	​	2026		​	2026		​
​	​ ​ ​	(Unaudited)		​ ​ ​	​		​
Assets	​	​	​	​	​	​	​
Current assets:	​	​	​	​	​	​	​
Cash and cash equivalents	​	$	45,435	​	$	56,395	​
Accounts receivable - trade, net of allowance for credit losses of $65 as of September 30, 2026 and June 30, 2026	​	​	125	​	​	—	​
Investments in debt securities (adjusted cost $31,342 and $31,689 as of September 30, 2026 and June 30, 2026, respectively - see Note 6)	​	​	31,219	​	​	31,644	​
Promissory note receivable and accrued interest	​	​	1,124	​	​	1,104	​
Prepaid expenses and other current assets	​	​	3,336	​	​	3,078	​
Total Current Assets	​	​	81,239	​	​	92,221	​
​	​	​	​	​	​	​	​
Restricted cash	​	​	228	​	​	228	​
Operating lease right-of-use asset, net of accumulated amortization	​	​	1,566	​	​	1,667	​
Fixed assets, net of accumulated depreciation	​	​	3,021	​	​	3,086	​
Intangible assets, net of accumulated amortization	​	​	2,570	​	​	1,825	​
Prepaid expenses - noncurrent	​	​	—	​	​	73	​
Security deposits	​	​	27	​	​	10	​
Total Assets	​	$	88,651	​	$	99,110	​
​	​	​	​	​	​	​	​
Liabilities and Stockholders’ Equity	​	​	​	​	​	​	​
Current liabilities:	​	​	​	​	​	​	​
Accounts payable	​	$	4,409	​	$	4,423	​
Accrued expenses	​	​	3,404	​	​	5,626	​
Operating lease obligation - current portion	​	​	561	​	​	546	​
Contract liabilities	​	​	200	​	​	1,150	​
Total Current Liabilities	​	​	8,574	​	​	11,745	​
​	​	​	​	​	​	​	​
Operating lease obligation - net of current portion	​	​	1,507	​	​	1,652	​
Total Liabilities	​	​	10,081	​	​	13,397	​
​	​	​	​	​	​	​	​
Stockholders’ Equity	​	​	​	​	​	​	​
Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 shares issued and outstanding (see Note 15)	​	​	—	​	​	—	​
Common Stock - $0.001 par value; 275,000,000 shares authorized; 64,307,256 and 55,698,561 shares issued and outstanding as of September 30, 2026 and June 30, 2026, respectively (see Note 15)	​	​	64	​	​	56	​
Additional paid-in capital	​	​	451,448	​	​	450,970	​
Accumulated other comprehensive loss	​	​	(123)	​	​	(45)	​
Accumulated deficit	​	​	(372,819)	​	​	(365,268)	​
Total Stockholders’ Equity	​	​	78,570	​	​	85,713	​
Total Liabilities and Stockholders’ Equity	​	$	88,651	​	$	99,110	​

​

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EX-99.1 176.3 KB

Other Documents

• EX-101 EX-101.SCH 3.4 KB
• EX-101 EX-101.DEF 3.5 KB
• EX-101 EX-101.LAB 16.9 KB
• EX-101 EX-101.PRE 11.1 KB